ZA200807596B - Improved crystalline material - Google Patents
Improved crystalline materialInfo
- Publication number
- ZA200807596B ZA200807596B ZA200807596A ZA200807596A ZA200807596B ZA 200807596 B ZA200807596 B ZA 200807596B ZA 200807596 A ZA200807596 A ZA 200807596A ZA 200807596 A ZA200807596 A ZA 200807596A ZA 200807596 B ZA200807596 B ZA 200807596B
- Authority
- ZA
- South Africa
- Prior art keywords
- crystalline material
- improved crystalline
- crystalline form
- improved
- phonoxy
- Prior art date
Links
- 239000002178 crystalline material Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Insulating Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0606201.2A GB0606201D0 (en) | 2006-03-28 | 2006-03-28 | Improved crytalline material |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200807596B true ZA200807596B (en) | 2009-11-25 |
Family
ID=36424732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200807596A ZA200807596B (en) | 2006-03-28 | 2008-09-03 | Improved crystalline material |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090239951A1 (xx) |
EP (2) | EP2368873A1 (xx) |
JP (1) | JP2009531358A (xx) |
KR (1) | KR20090014342A (xx) |
CN (1) | CN101421229A (xx) |
AT (1) | ATE550314T1 (xx) |
AU (1) | AU2007229718A1 (xx) |
BR (1) | BRPI0710120A2 (xx) |
CA (1) | CA2642872A1 (xx) |
GB (1) | GB0606201D0 (xx) |
MX (1) | MX2008012393A (xx) |
NO (1) | NO20083588L (xx) |
NZ (1) | NZ570684A (xx) |
RU (1) | RU2444513C2 (xx) |
WO (1) | WO2007110225A1 (xx) |
ZA (1) | ZA200807596B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
DK2695611T3 (en) | 2012-08-06 | 2015-01-05 | Wolff August Gmbh & Co Kg Arzneimittel Dr | Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3450751A (en) * | 1963-06-15 | 1969-06-17 | Noguchi Inst The | Continuous optical resolution of racemic glutamic acid or its salts |
GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
KR100740383B1 (ko) * | 2000-02-17 | 2007-07-16 | 브리스톨-마이어스스퀴브컴파니 | 갑상선 수용체에 대한 아닐린 유도 리간드 |
SK13762002A3 (sk) * | 2000-03-31 | 2004-01-08 | Pfizer Products Inc. | Malonámové kyseliny a ich deriváty ako ligandy tyreoideálnych receptorov |
AU4884701A (en) * | 2000-05-12 | 2001-11-20 | Kissei Pharmaceutical Co. Ltd. | Malonanilic acid derivatives, medicinal compositions containing the same and usethereof |
WO2002083480A1 (en) | 2001-04-12 | 2002-10-24 | Mtd Products Inc | Four-wheel steering system |
JP4225791B2 (ja) * | 2001-05-18 | 2009-02-18 | キッセイ薬品工業株式会社 | 肝癌の予防または再発抑制剤 |
US6806381B2 (en) * | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
TW200504021A (en) * | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
-
2006
- 2006-03-28 GB GBGB0606201.2A patent/GB0606201D0/en not_active Ceased
-
2007
- 2007-03-27 CN CNA2007800108211A patent/CN101421229A/zh active Pending
- 2007-03-27 AU AU2007229718A patent/AU2007229718A1/en not_active Abandoned
- 2007-03-27 AT AT07723633T patent/ATE550314T1/de active
- 2007-03-27 JP JP2009501928A patent/JP2009531358A/ja active Pending
- 2007-03-27 MX MX2008012393A patent/MX2008012393A/es not_active Application Discontinuation
- 2007-03-27 KR KR1020087025952A patent/KR20090014342A/ko not_active Application Discontinuation
- 2007-03-27 EP EP11171176A patent/EP2368873A1/en not_active Withdrawn
- 2007-03-27 BR BRPI0710120-1A patent/BRPI0710120A2/pt not_active IP Right Cessation
- 2007-03-27 NZ NZ570684A patent/NZ570684A/en not_active IP Right Cessation
- 2007-03-27 RU RU2008142528/04A patent/RU2444513C2/ru not_active IP Right Cessation
- 2007-03-27 EP EP07723633A patent/EP2004593B1/en not_active Not-in-force
- 2007-03-27 WO PCT/EP2007/002687 patent/WO2007110225A1/en active Application Filing
- 2007-03-27 US US12/225,630 patent/US20090239951A1/en not_active Abandoned
- 2007-03-27 CA CA002642872A patent/CA2642872A1/en not_active Abandoned
-
2008
- 2008-08-19 NO NO20083588A patent/NO20083588L/no not_active Application Discontinuation
- 2008-09-03 ZA ZA200807596A patent/ZA200807596B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ATE550314T1 (de) | 2012-04-15 |
CN101421229A (zh) | 2009-04-29 |
NO20083588L (no) | 2008-11-12 |
EP2004593A1 (en) | 2008-12-24 |
US20090239951A1 (en) | 2009-09-24 |
CA2642872A1 (en) | 2007-10-04 |
WO2007110225A1 (en) | 2007-10-04 |
AU2007229718A1 (en) | 2007-10-04 |
KR20090014342A (ko) | 2009-02-10 |
MX2008012393A (es) | 2009-03-02 |
RU2008142528A (ru) | 2010-05-10 |
EP2368873A1 (en) | 2011-09-28 |
GB0606201D0 (en) | 2006-05-10 |
EP2004593B1 (en) | 2012-03-21 |
NZ570684A (en) | 2011-07-29 |
JP2009531358A (ja) | 2009-09-03 |
RU2444513C2 (ru) | 2012-03-10 |
BRPI0710120A2 (pt) | 2011-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200807596B (en) | Improved crystalline material | |
IL223412A0 (en) | Process for producing pesticidal benzamide compounds | |
WO2008123046A1 (ja) | チタン酸カリウム及びその製造方法並びに摩擦材及び樹脂組成物 | |
TW200716558A (en) | Heteroaroyl-substituted serineamides | |
SI2076501T1 (sl) | Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline | |
BRPI0804994A2 (pt) | forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a | |
IL186795A0 (en) | The planting of plant material | |
HK1143140A1 (en) | Novel compounds 951: a biphenyloxypropanoic acid as crth2 modulator and intermediates | |
BRPI0603059A (pt) | forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a | |
HK1199885A1 (en) | Crystalline forms of (3s)-3-[n-(n-(2-tert- butylphenyl)oxamyl)alaniwyl]amino-5-(2,3,5,6-tetrafluoro phenoxy)-4-0x0penta noic acid (3s)-3-[n-(n-(2-))]-5-(2356- )-4- | |
GEP20094577B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
FR2921376B1 (fr) | Compose styryl tetrahydroquinolinium thiol/disulfure, procede d'eclaircissement des matieres keratiniques a partir de ce colorant | |
ZA200802046B (en) | A process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol | |
ZA200804330B (en) | Tissue product having a transferable additive composition | |
WO2009103666A3 (en) | Process for the iodination of aromatic compounds | |
ZA200800729B (en) | A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it | |
IL182095A0 (en) | Process for making phenoxy benzamide compounds | |
EP2188078A4 (en) | CALCIUM-ENRICHED FIRE-RESISTANT MATERIAL BY ADDING A CALCIUM CARBONATE | |
ZA201100422B (en) | 1,2-benzisothiazole compounds useful for combating animal pests | |
HRP20130597T1 (xx) | Difosfatna sol od n-[6-cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(trifluorometoksi)[1,1'-bifenil]-3-karboksamida | |
IL239198A0 (en) | A method for identifying plant material showing reduced color fading, plants so identified and using identified plants to produce a commercial plant crop showing reduced color fading | |
ZA200900208B (en) | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | |
WO2011108752A3 (en) | Plant disease controlling composition and method for controlling plant disease | |
WO2009002489A3 (en) | Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin | |
WO2008081041A3 (en) | Amorphous and crystalline forms of rivastigmine hydrogentartrate |